International Study Monitoring Real-time Cannabis Treatment for the Symptoms of Endometriosis Will Leverage Strainprint's Comprehensive Research Platform
TORONTO, Nov. 15, 2018 /PRNewswire/ - Strainprint™ Technologies Ltd., the leader in cannabis data and analytics, today announced a partnership with Israeli research leaders, Lumir Lab and Gynica to conduct the world's first international clinical study on the use of cannabis to treat endometriosis. Endometriosis, a condition where tissue from the uterine lining migrates to other organs inside the body affects roughly 180 million women worldwide. It is estimated that 1 in 10 women between the ages of 15 to 49 will be affected by symptoms of endometriosis during their lifetime.
Strainprint's VP of Research, Michelle Arbus, will work closely with world-renowned cannabis scientist, Professor Lumir Hanus, along with Gynica's Professor Moshe Hod, President of the European Association of Perinatal Medicine and Professor of Obstetrics and Gynecology at Tel Aviv University medical school. The intention of the study is to develop clinically-validated cannabinoid-based products that can be approved for international distribution. Gynica holds a federal license by the Israeli Ministry of Health to research the effects of cannabinoids on women's health and gynecological disorders.
"Endometriosis remains one of the most misdiagnosed and least understood medical conditions, and currently, there is no cure," said Professor Hod. "Strainprint's early observational studies show that medical cannabis treatment has a positive effect on symptoms related to endometriosis, but much more research is required. Our objective is to identify which active cannabinoids, terpenes, and flavonoids, in relative combination, provide the most effective relief, reduce pain and prevent reoccurrence."
Simultaneous studies in both Israel and Canada will leverage Strainprint's research-ready platform to provide ethics approval, validated questionnaires, custom surveys, real-time treatment tracking and data visualization in support of in-clinic visits. Gynica Senior scientist, Dr. Sari Prutchi Sagiv, will develop the joint-study protocol to be used for clinical trial applications in both countries, based on a common product formulation. Drawing first from Strainprint's 900,000+ real-time patient outcomes and 40 million medical cannabis data points, Lumir Lab will narrow and validate a formulation to focus on at the study. Together, the parties will use Strainprint's recently launched community portal to recruit up to 1,000 patients in each country.
Dr. Prutchi Sagiv says "The combination of Strainprint's big data analytics combined with Gynica's scientific team and clinical research capabilities create a unique and innovative approach for providing evidence-based products to patients worldwide, and moreover for women who are under-treated by current solutions."
Gynica, Lumir Lab and Strainprint expect the clinical study to run on Q2 of 2019.
"It's truly amazing for all of us at Strainprint to get to work with this team of world-renowned scientists and doctors on such a significant medical issue," said Strainprint CEO, Andrew Muroff. "We're committed to helping improve the lives of millions of women suffering from endometriosis."
Founded in Toronto in 2016, StrainprintTM Technologies Ltd. is the leading demand-side cannabis data and analytics company. With the world's largest longitudinal, observational data-set of its kind and a mission to advance the scientific understanding of cannabis and its legitimization as a mainstream therapy, Strainprint helps medical cannabis patients and doctors to use cannabis in the most effective and responsible way possible. StrainprintTM data platform supports global cannabis research and provides advanced business intelligence and treatment guidance to producers, retailers, medical practitioners, pharmacies, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted and all patient data is completely anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR) and seed2sale software systems. Strainprint Analytics is accessed by customer subscription. The Strainprint App is free to patients and can be downloaded from both the iOS App Store and GooglePlay Store. www.strainprintanalytics.com. facebook, twitter, linkedin.
Gynica focuses on clinically proven cannabis-based solutions in the field of women's health, developing optimal therapeutic results based on innovative technology and understanding of the pharmacological effects of different cannabinoids and compounds, targeted to specific female-related diseases. The team is led by the President of the European Association of Perinatal Medicine, Professor Moshe Hod, who is also a Tel Aviv University medical school professor of obstetrics and gynecology. Gynica is owned by Asana Bio Group, an Israeli holding company specializing in scientific advancements in the field of medical cannabis.
About Lumir Lab.
Lumir Lab is a research & development lab focused on cannabinoids, led by Prof. Lumír Ondřej Hanuš, a world-renowned analytical chemist and a leading figure in the field of cannabis research, who is responsible for some of the greatest discoveries in the field of cannabis. During his career of 49 years as a cannabis researcher, he isolated and identified the first known endocannabinoid in the human brain, Anandamide. Lumir Lab has established a world-leading position in the development of cannabinoid-based therapeutics through analytical methods and clinical validation, offering a wide range of solutions for companies operating in the medical cannabis industry. Lumir Lab is owned by Asana Bio Group, an Israeli holding company specializing in scientific advancements in the field of medical cannabis.
SOURCE Strainprint Technologies Ltd.